NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...
A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The ...
Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...
compared to AstraZeneca's (AZN.L), opens new tab blockbuster drug Tagrisso. The combination of J&J's cancer drugs Rybrevant and lazertinib was approved in August for a type of non-small cell lung ...
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
CNW/ -- (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth ...
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.